Publication Date:
2012-01-31
Description:
G-protein-coupled receptors are the largest class of cell-surface receptors, and these membrane proteins exist in equilibrium between inactive and active states. Conformational changes induced by extracellular ligands binding to G-protein-coupled receptors result in a cellular response through the activation of G proteins. The A(2A) adenosine receptor (A(2A)AR) is responsible for regulating blood flow to the cardiac muscle and is important in the regulation of glutamate and dopamine release in the brain. Here we report the raising of a mouse monoclonal antibody against human A(2A)AR that prevents agonist but not antagonist binding to the extracellular ligand-binding pocket, and describe the structure of A(2A)AR in complex with the antibody Fab fragment (Fab2838). This structure reveals that Fab2838 recognizes the intracellular surface of A(2A)AR and that its complementarity-determining region, CDR-H3, penetrates into the receptor. CDR-H3 is located in a similar position to the G-protein carboxy-terminal fragment in the active opsin structure and to CDR-3 of the nanobody in the active beta(2)-adrenergic receptor structure, but locks A(2A)AR in an inactive conformation. These results suggest a new strategy to modulate the activity of G-protein-coupled receptors.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303121/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉 〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303121/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Hino, Tomoya -- Arakawa, Takatoshi -- Iwanari, Hiroko -- Yurugi-Kobayashi, Takami -- Ikeda-Suno, Chiyo -- Nakada-Nakura, Yoshiko -- Kusano-Arai, Osamu -- Weyand, Simone -- Shimamura, Tatsuro -- Nomura, Norimichi -- Cameron, Alexander D -- Kobayashi, Takuya -- Hamakubo, Takao -- Iwata, So -- Murata, Takeshi -- 062164/Z/00/Z/Wellcome Trust/United Kingdom -- BB/G023425/1/Biotechnology and Biological Sciences Research Council/United Kingdom -- England -- Nature. 2012 Jan 29;482(7384):237-40. doi: 10.1038/nature10750.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Iwata Human Receptor Crystallography Project, ERATO, Japan Science and Technology Agency, Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8501, Japan.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/22286059" target="_blank"〉PubMed〈/a〉
Keywords:
Allosteric Regulation/*drug effects
;
Animals
;
Antibodies, Monoclonal/immunology/*pharmacology
;
Complementarity Determining Regions/immunology
;
*Drug Inverse Agonism
;
Humans
;
Immunoglobulin Fab Fragments/immunology/pharmacology
;
Ligands
;
Mice
;
Models, Molecular
;
Opsins/immunology
;
Pichia
;
Protein Conformation/drug effects
;
Receptor, Adenosine A2A/chemistry/immunology/*metabolism
;
Receptors, G-Protein-Coupled/agonists/*antagonists &
;
inhibitors/chemistry/*immunology
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
